Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / September 9, 2026 /Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ:RARE). Investors who purchased Ultragenyx securities are encouraged to obtain additional information and assist the investigation by visiting the firm 's site: bgandg.com/cases/ultragenyx-pharmaceutical-inc-rare-class_action_lawsuit.
Ultragenyx Investigation Details
On September 2, 2026, Ultragenyx issued a press release "announcing results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome." Per the press release, "[t]he study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)." On this news, Ultragenyx 's stock price fell $11.68 per share, or 44.03%, to close at $14.85 per share on September 3, 2026.
What 's Next for Ultragenyx Investors?
If you are aware of any facts relating to this investigation or purchased Ultragenyx securities, you can assist this investigation by visiting the firm 's site: bgandg.com/cases/ultragenyx-pharmaceutical-inc-rare-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Ultragenyx Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys ' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Ultragenyx Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE:Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
